About this Research Topic
Immunotherapy has become a promising treatment for various types of cancer. However, the population that benefits from immunotherapy is still limited. To improve the treatment outcomes of individuals with malignant tumors, it is crucial to develop novel immunotherapy strategies. This Research Topic aims to showcase original research and reviews on detecting potential targets for immunotherapy and developing novel immunotherapy strategies, with a focus on cancer treatment.
We invite studies that investigate the relationship between molecular signatures and the tumor immune microenvironment using multi-omics sequencing techniques, including genomic and transcriptomic analysis of individual cells, immune infiltration analysis strategies, tumor neo-antigen design techniques, and tumor-specific vaccine preparation. We also encourage research on identifying potential immunotherapeutic targets, with a focus on biomarkers that can predict the sensitivity of current immunotherapies like immune checkpoint inhibitors and small molecule immune drugs.
Moreover, we prioritize studies related to the development of novel immunotherapy strategies, such as neo-antigens, tumor-specific vaccines, and immune checkpoint inhibitors, as well as processes like HLA subtype identification. We encourage large-scale data integration, along with computational analysis and experimental validation. Additionally, we welcome studies on developing combinational strategies of immunotherapy and other treatments or combinational immunotherapy strategies.
In summary, this Research Topic aims to cover the following topics:
• Investigating the association between molecular characteristics and the immune microenvironment from a multi-omics perspective
• Exploring potential novel immunotherapeutic targets and experimentally verifying their efficacy
• Identifying the possible mechanism of potential immunotherapeutic targets on tumor-associated pathways or biological processes
• Exploring biomarkers associated with immunotherapy sensitivity and identifying patients with positive immunotherapy outcomes
• Developing novel immunotherapy strategies such as tumor neo-antigens and tumor-specific vaccines and validating them in vitro or in vivo
• Developing combinational strategies of immunotherapy and other treatments or combinational immunotherapy strategies
• Analyzing VDJ gene preference in TCRs or BCRs, and HLA identification based on single-cell sequencing datasets
• Developing novel immune cellular therapies based on T cells and B cells.
Please note the following:
1) Original research based solely on in silico techniques will not be considered for review.
2) Following the general standards for Frontiers in Pharmacology, effect in a minimum of 2 cell-lines in vitro is the minimum evidential basis to demonstrate proposed anti-cancer effect in all relevant submissions.
We invite studies that investigate the relationship between molecular signatures and the tumor immune microenvironment using multi-omics sequencing techniques, including genomic and transcriptomic analysis of individual cells, immune infiltration analysis strategies, tumor neo-antigen design techniques, and tumor-specific vaccine preparation. We also encourage research on identifying potential immunotherapeutic targets, with a focus on biomarkers that can predict the sensitivity of current immunotherapies like immune checkpoint inhibitors and small molecule immune drugs.
Moreover, we prioritize studies related to the development of novel immunotherapy strategies, such as neo-antigens, tumor-specific vaccines, and immune checkpoint inhibitors, as well as processes like HLA subtype identification. We encourage large-scale data integration, along with computational analysis and experimental validation. Additionally, we welcome studies on developing combinational strategies of immunotherapy and other treatments or combinational immunotherapy strategies.
In summary, this Research Topic aims to cover the following topics:
• Investigating the association between molecular characteristics and the immune microenvironment from a multi-omics perspective
• Exploring potential novel immunotherapeutic targets and experimentally verifying their efficacy
• Identifying the possible mechanism of potential immunotherapeutic targets on tumor-associated pathways or biological processes
• Exploring biomarkers associated with immunotherapy sensitivity and identifying patients with positive immunotherapy outcomes
• Developing novel immunotherapy strategies such as tumor neo-antigens and tumor-specific vaccines and validating them in vitro or in vivo
• Developing combinational strategies of immunotherapy and other treatments or combinational immunotherapy strategies
• Analyzing VDJ gene preference in TCRs or BCRs, and HLA identification based on single-cell sequencing datasets
• Developing novel immune cellular therapies based on T cells and B cells.
Please note the following:
1) Original research based solely on in silico techniques will not be considered for review.
2) Following the general standards for Frontiers in Pharmacology, effect in a minimum of 2 cell-lines in vitro is the minimum evidential basis to demonstrate proposed anti-cancer effect in all relevant submissions.
Keywords: cancer, multi-omics, immunotherapy, immune microenvironment, therapeutic targets, neoantigens, tumor vaccines, immune checkpoint inhibitors
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
